Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease - PubMed

Review

Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease

Mark H Tuszynski et al. Prog Brain Res. 2004.

Abstract

Over the last 20 years it has been recognized that neurotrophic factors profoundly influence the development of the nervous system and have the potential to modify disease processes in the adult nervous system. The ability of nervous system growth factors to prevent or reduce neuronal degeneration in animal models of neurodegenerative diseases has led to several clinical trials. One of the main obstacles to the success of these trials has been the method of growth factor delivery: sufficiently high doses of neurotrophic factors must be achieved in the target region of the brain to efficiently modify disease processes, but delivery must be restricted to specific brain regions to prevent adverse effects. Recent advances in molecular medicine have made gene therapy in the nervous system a potentially realistic approach for the delivery of therapeutic molecules such as growth factors. As an alternative to conventional drug delivery, several gene therapy trials for the treatment of central nervous system diseases have started or will start in the near future. This chapter reviews the development of neurotrophic factor gene therapy for neurodegenerative diseases focusing on the therapeutic potential of nerve growth factor in Alzheimer's disease, currently the subject of a phase I clinical trial.

Similar articles

• Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.

  Tuszynski MH, Yang JH, Barba D, U HS, Bakay RA, Pay MM, Masliah E, Conner JM, Kobalka P, Roy S, Nagahara AH. Tuszynski MH, et al. JAMA Neurol. 2015 Oct;72(10):1139-47. doi: 10.1001/jamaneurol.2015.1807. JAMA Neurol. 2015. PMID: 26302439 Free PMC article. Clinical Trial.

• Nerve growth factor gene therapy in Alzheimer disease.

  Tuszynski MH. Tuszynski MH. Alzheimer Dis Assoc Disord. 2007 Apr-Jun;21(2):179-89. doi: 10.1097/WAD.0b013e318068d6d2. Alzheimer Dis Assoc Disord. 2007. PMID: 17545746 Review.

• Nerve growth factor gene delivery: animal models to clinical trials.

  Tuszynski MH. Tuszynski MH. Dev Neurobiol. 2007 Aug;67(9):1204-15. doi: 10.1002/dneu.20510. Dev Neurobiol. 2007. PMID: 17514712 Review.

• Cholinergic strategies for Alzheimer's disease.

  Winkler J, Thal LJ, Gage FH, Fisher LJ. Winkler J, et al. J Mol Med (Berl). 1998 Jul;76(8):555-67. doi: 10.1007/s001090050250. J Mol Med (Berl). 1998. PMID: 9694432 Review.

• Intraparenchymal NGF infusions rescue degenerating cholinergic neurons.

  Tuszynski MH. Tuszynski MH. Cell Transplant. 2000 Sep-Oct;9(5):629-36. doi: 10.1177/096368970000900508. Cell Transplant. 2000. PMID: 11144960

Cited by

• Gene delivery to the spinal cord: comparison between lentiviral, adenoviral, and retroviral vector delivery systems.

  Abdellatif AA, Pelt JL, Benton RL, Howard RM, Tsoulfas P, Ping P, Xu XM, Whittemore SR. Abdellatif AA, et al. J Neurosci Res. 2006 Aug 15;84(3):553-67. doi: 10.1002/jnr.20968. J Neurosci Res. 2006. PMID: 16786574 Free PMC article.

• Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences.

  Redzic Z. Redzic Z. Fluids Barriers CNS. 2011 Jan 18;8(1):3. doi: 10.1186/2045-8118-8-3. Fluids Barriers CNS. 2011. PMID: 21349151 Free PMC article.

• Evaluation of neural damage in Duchenne muscular dystrophy patients.

  Salam EA, Abdel-Meguid IE, Shatla R, Korraa S. Salam EA, et al. Acta Myol. 2014 May;33(1):13-8. Acta Myol. 2014. PMID: 24843230 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program